05/05 Taiwan BIO Weekly
2026-05-05 |
| Taiwan BIO Weekly |
| Regenerative medicine firm Locus Cell opens plant in northern Taiwan 30 April, 2026 A Taiwan-based contract manufacturer of cells for regenerative medicine is hoping to expand business with Japanese biotechnology firms with its new factory in northern Taiwan More... |
| Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases Press release 30 April, 2026 Formosa Pharmaceuticals, Inc. (TW: 6838) and the Singapore Eye Research Institute are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa's proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. More... |
| Medigen Vaccine Biologics submits enterovirus vaccine NDA in the Philippines 30 April, 2026 Medigen Vaccine Biologics (TW: 6547) has submitted a New Drug Application (NDA) for its EnVax-A71 enterovirus 71 vaccine to the Philippines FDA. Earlier in 2026, the company secured its first EV71 vaccine approval in Vietnam and as part of its Southeast Asia expansion strategy has partnered with regional collaborators to file regulatory submissions in Singapore, Malaysia, Thailand, and the Philippines. Medigen Vaccine Biologics plans to continue advancing overseas registrations to broaden the global footprint of its enterovirus vaccine. The Philippines faces persistent enterovirus outbreaks, with nearly 40,000 reported cases by mid-August 2025, more than six times higher year-on-year. With around 1.36 million annual births and no approved enterovirus vaccine currently available, there is significant unmet demand for safe and effective immunization solutions in the country. More... (in Chinese) |
| MegaPro Biomedical accelerates pipeline with dual nanotech platforms 30 April, 2026 MegaPro Biomedical (TW: 6827) said at its investor conference on 29th April that it has established dual nanotechnology platforms (Nanoparticle™ and NanoMicelle™) with its pipeline entering a key value inflection phase. Its liver cancer MRI contrast agent MPB-1523 is expected to enter Phase III clinical trials in the third quarter, while MPB-1734, a new formulation for prostate cancer, is planned to begin bioequivalence studies by year-end. The company aims to file for regulatory approval in 2028 and obtain market approvals for both products in 2029. More... (in Chinese) |
| Energenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026 Press release 29 April, 2026 Energenesis Biomedical Co., Ltd. (TW: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application experience of its investigational drug candidate ENERGI-F703DFU at the European Wound Management Association (EWMA) 2026 Annual Conference, to be held May 5-7, 2026, in Bremen, Germany. More... |
| Hsiao says Taiwan a reliable partner in global health 29 April, 2026 Vice President Hsiao Bi-khim said Wednesday that Taiwan has become a reliable partner in the global medical community, citing EU recognition of its pharmaceutical standards. In a recorded speech for the Taiwan–Europe Health Forum, Hsiao said the EU has recognized Taiwan as a third country for active pharmaceutical ingredients exported to Europe, per CNA. She also noted Taiwan's associate membership in the International Coalition of Medicines Regulatory Authorities. More... |
| Hong Kong Patient Overcomes Four IVF Failures with Taiwan NUWA Healthcare's Precision Medicine; Taiwan Emerges as Leading Fertility Hub with One-Third the Cost of US and HK Press release 29 April, 2026 A 38-year-old Hong Kong woman has successfully achieved pregnancy and "graduated" from her fertility journey after four previous failed IVF attempts in Hong Kong. The breakthrough came under the care of Dr. Cheng-Hsuan Wu, Vice Director of NUWA Fertility Center in Taichung, whose medical intervention identified a long-overlooked case of chronic endometritis and utilized advanced PGT-A and ERA screening technologies to ensure a successful embryo transfer. More... |
| EirGenix Advances into CPHI Japan, Capitalizing on Market Trends to Deepen Its Strategic Footprint in Japan 28 April, 2026 As the global biopharmaceutical industry undergoes rapid restructuring, two powerful forces, policy evolution and supply chain transformation, are reshaping Japan's landscape. On one side, the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have built a solid regulatory framework to accelerate biosimilar development. On the other hand, geopolitical risks and economic policy shifts are driving a stronger focus on domestic production capacity and supply chain resilience. These trends are prominently on display at CPHI Japan 2026, where EirGenix (TW: 6589) is actively expanding its presence to solidify its long-term position in the Japanese market. More... |
| Anbogen Therapeutics signs MOU with investment firm GEM, up to US$150M injection mentioned 28 April, 2026 Anbogen Therapeutics (TW: 7784) announced that it has signed an MOU with investment firm Global Emerging Markets (GEM) under which GEM may provide up to US$150 million in strategic investment funding, following a detailed evaluation of Anbogen Therapeutics' oncology drug pipeline. The company said the partnership reflects strong international recognition of its capabilities in small-molecule precision cancer drug development, and the funds will be used to support ongoing clinical trials and further expand its R&D programs, strengthening its position in the cancer drug development value chain. More... (in Chinese) |
| TPIsoftware Wins "Taiwan SMART 50 Award" for Its FHIR-Based Medical AI Application Press release 27 April, 2026 TPIsoftware (TW: 7781) was honored with the first Taiwan SMART 50 Award for creating a FHIR-based Medical AI Application. Organized by the Ministry of Health and Welfare, the award encourages the development of smart health apps that align with the SMART on FHIR standard to enable secure and real-time data sharing across different hospitals. 50 apps were selected from 115 submissions through an open call. These apps will be listed on the Taiwan Health App Space (THAS) as part of the country's initiative to foster data interoperability in healthcare. More... |
| Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials Press release 27 April, 2026 PharmaEssentia Corporation (TW: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that Taiwan's Representative to the United States Alexander Tah-ray Yui and Mme. Karen Lo, accompanied by Charles Chi Yu Chou, Director General of Taipei Economic and Cultural Office (TECO) Miami, and Felipe Tsai, Deputy Director of TECO Miami, visited PharmaEssentia's Puerto Rico facility on April 20 (Eastern Time). This marks the second high-level visit by a Taiwan government official to PharmaEssentia's overseas operations -- following the May 2023 visit by then-Representative Hsiao Bi-khim (now Vice President of Taiwan) to the company's US subsidiary in Boston -- underscoring the Taiwan government's strong commitment to supporting the international expansion of Taiwan's biotechnology industry. More... |
| Gongwin Biopharm teams up with partners to advance lung cancer drug rollout in China 26 April, 2026 Gongwin Biopharm Holdings (TW: 6617) announced a strategic shift as its subsidiary Tianjin Hongri Jiandakang Pharmaceutical Technology signed a commercialization partnership with Zhenshi Biomedical Technology to support the mainland China market (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zhenshi will assist in the commercialization of Gongwin’s Proxian product by handling key functions such as product positioning, market strategy, competitive analysis, market access planning, promotional activities, annual medical and marketing programs, channel development, and safety monitoring. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |